Tatjana Welzel

Dr. Tatjana Welzel

University Children's Hospital Basel, University of Basel, Basel, Switzerland
+1
orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2021 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
TWTatjana Welzel
Tatjana Welzel
Jasmin Kuemmerle-DeschnerJasmin Kuemmerle-Deschner
Jasmin Kuemmerle-Deschner
The cryopyrin-associated periodic syndromes (CAPS) are usually caused by heterozygous NLRP3 gene variants, resulting in excessive inflammasome activation with subsequent overproduction of interleukin (IL)-1β. The CAPS spectrum includes mild, moderate, and severe phenotypes. The mild phenotype is called familial cold autoinflammatory syndrome (FCAS), the moderate phenotype is also known as Muckle–Wells syndrome (MWS), and the neonatal-onset multisystem inflammatory disease (NOMID)/chronic infantile neurologic cutaneous articular syndrome (CINCA) describes the severe phenotype. The CAPS phenotypes display unspecific and unique clinical signs. Dermatologic, musculoskeletal, ocular, otologic, and neurologic disease symptoms combined with chronic systemic inflammation are characteristic. Nevertheless, making the CAPS diagnosis is challenging as several patients show a heterogeneous multi-system clinical presentation and the spectrum of genetic variants is growing. Somatic mosaicisms and low-penetrance variants lead to atypical clinical symptoms and disease courses. To avoid morbidity and to reduce mortality, early diagnosis is crucial, and a targeted anti-IL-1 therapy should be started as soon as possible. Furthermore, continuous and precise monitoring of disease activity, organ damage, and health-related quality of life is important. This review summarizes the current evidence in diagnosis and management of patients with CAPS.

7 April 2020 in Rheumatology
Verified
Journal Article
Closed access
JKJasmin B Kuemmerle-Deschner
Jasmin B Kuemmerle-Deschner
TWTatjana Welzel
Tatjana Welzel
KHKonstanze Hoertnagel
Konstanze Hoertnagel
ITIlias Tsiflikas
Ilias Tsiflikas
AHAnton Hospach
Anton Hospach
AWAlexander N Weber
Alexander N Weber
Objective: To report a chronic recurrent multifocal osteomyelitis (CRMO)-like clinical phenotype with multisystem inflammation associated with a novel gene variant in the spectrum of IL-1-mediated diseases. Methods: A 3-year-old boy presented with recurrent episodes of fever, serositis, pancreatitis and high inflammatory markers with onset at age 13 months. At age 3 years, he started limping. Imaging revealed multifocal pelvic bone inflammation suggestive of CRMO. Autoinflammation panel testing was non-contributory. Whole exome sequencing (WES) and advanced IL-1 pathway analysis was conducted. Results: WES identified a novel homozygous interleukin receptor 1 (IL1RN) variant (c.62C>G; p. Ser21*) (NM_173842.2). Functional analysis of IL1RN mRNA and IL-1 receptor antagonist (IL-1RA) protein confirmed the diagnosis of a deficiency of the IL-1 receptor antagonist (DIRA). Treatment with the nonselective IL-1 inhibitor anakinra resulting in rapid remission; switch to the selective IL-1β antagonist canakinumab led to a flare within 6 weeks. Re-start of anakinra recaptured remission, last documented at the recent 19-month follow-up. Conclusion: This is the first report of a novel late-onset DIRA confirmed by advanced diagnostic testing. In patients with systemic inflammation and CRMO-like bone lesions, IL1RN testing should be considered; even in the absence of skin manifestations. Non-selective IL-1 inhibition is an effective therapy.

25 March 2021 in Pediatric Rheumatology
Verified
Journal Article
Open access
PDF file
TWTatjana Welzel
Tatjana Welzel
CWCarolyn Winskill
Carolyn Winskill
NZNancy Zhang
Nancy Zhang
AWAndreas Woerner
Andreas Woerner
MPMarc Pfister
Marc Pfister
Background: Biologic disease modifying antirheumatic drugs (bDMARDs) and Janus Kinase (JAK) inhibitors are prescribed in adult and paediatric rheumatology. Due to age-dependent changes, disease course, and pharmacokinetic processes paediatric patients with inflammatory rheumatic diseases (PiRD) differ from adult rheumatology patients.Methods: A systematic literature search for randomized clinical trials (RCTs) in PiRD treated with bDMARDs/JAK inhibitors was conducted on Medline,clinicaltrials.gov, clinicaltrialsregister.eu and conference abstracts as of July 2020. RCTs were included if (i) patients were aged ≤20 years, (ii) patients had a predefined rheumatic diagnosis and (iii) RCT reported predefined outcomes. Selected studies were excluded in case of (i) observational or single arm study or (ii) sample size ≤5 patients. Study characteristics were extracted.Results: Out of 608 screened references, 65 references were selected, reporting 35 unique RCTs. All 35 RCTs reported efficacy while 34/35 provided safety outcomes and 16/35 provided pharmacokinetic data. The most common investigated treatments were TNF inhibitors (60%), IL-1 inhibitors (17%) and IL-6 inhibitors (9%). No RCTs with published results were identified for baricitinib, brodalumab, certolizumab pegol, guselkumab, risankizumab, rituximab, sarilumab, secukinumab, tildrakizumab, or upadacitinib. In patients with juvenile idiopathic arthritis (JIA) 25/35 RCTs were conducted. The remaining 10 RCTs were performed in non-JIA patients including plaque psoriasis, Kawasaki Disease, systemic lupus erythematosus and non-infectious uveitis. In JIA-RCTs, the control arm was mainly placebo and the concomitant treatments were either methotrexate, non-steroidal anti-inflammatory drugs (NSAID) or corticosteroids. Non-JIA patients mostly received NSAID. There are ongoing trials investigating abatacept, adalimumab, baricitinib, brodalumab, certolizumab pegol, etanercept, guselkumab, infliximab, risankizumab, secukinumab, tofacitinib and tildrakizumab.Conclusion: Despite the FDA Modernization Act and support of major paediatric rheumatology networks, such as the Pediatric Rheumatology Collaborative Study Group (PRCSG) and the Paediatric Rheumatology International Trials Organization (PRINTO), which resulted in drug approval for PiRD indications, there are limited RCTs in PiRD patients. As therapy response is influenced by age-dependent changes, pharmacokinetic processes and disease course it is important to consider developmental changes in bDMARDs/JAK inhibitor use in PiRD patients. As such it is critical to collaborate and conduct international RCTs to appropriately investigate and characterize efficacy, safety and pharmacokinetics of bDMARDs/JAK inhibitors in paediatric rheumatology.

17 May 2022 in Rheumatology
Verified
Journal Article
Closed access
PDF file
AWAlexander Weber
Alexander Weber
ATAna Tapia-Abellán
Ana Tapia-Abellán
XLXiao Liu
Xiao Liu
SDSabine Dickhöfer
Sabine Dickhöfer
JAJuan I Aróstegui
Juan I Aróstegui
JKJasmin B Kuemmerle-Deschner
Jasmin B Kuemmerle-Deschner
Dear Editor, The NLR Family Pyrin Domain Containing 3 (NLRP3) inflammasome is an essential inflammation driver linked to multiple human diseases, such as gout or Alzheimer’s disease, but is also the genetic cause for cryopyrin-associated periodic syndrome (CAPS) [ 1]. In CAPS, numerous NLRP3 gain-of-function mutations [ 2] can cause a continuous disease spectrum [ 3, 4]: mild familial cold auto-inflammatory syndrome (FCAS), intermediate Muckle–Wells syndrome (MWS) and severe neonatal-onset multisystem inflammatory disease (NOMID). Typical are spontaneous inflammatory flares and/or chronic inflammation mainly affecting the eyes, skin, muscles, joints, bones, kidneys and central nervous system. Early diagnosis and effective treatment are crucial. As IL-1 plays a central role in CAPS pathogenesis, treatment recommendations include subcutaneous anti-IL-1 therapy [ 5]. However, this is challenging in children and also fails to neutralize other NLRP3-dependent alarmins. Therefore, oral pharmacological inhibitors specifically targeting NLRP3 would be highly desirable for clinical CAPS management. The NLRP3-specific research-only compound MCC950/CRID3 [ 6] has prominently provided a proof-of-concept for blocking NLRP3 in vitro and in multiple murine in vivo disease models. Although MCC950 efficacy for unmutated NLRP3 is unequivocal, a recent study by Vande Walle et al. [ 7] into the effect of MCC950 on CAPS high-penetrance mutations challenged its efficacy in CAPS. Their conclusion—mainly based on cell lines or murine models—that MCC950 could be not effective in CAPS was echoed in the field and strongly dampened enthusiasm for the development of small molecule antagonists of NLRP3.

17 September 2020 in Children
Verified
Journal Article
Open access
PDF file
Eveline StaubEveline Staub
Eveline Staub
NUNatalie Urfer-Maurer
Natalie Urfer-Maurer
SLSakari Lemola
Sakari Lemola
Lorenz RischLorenz Risch
Lorenz Risch
KEKatrina Suzanne Evers
Katrina Suzanne Evers
MPMarc Pfister
Marc Pfister
Background: Preterm infants are at an increased risk of developing hypertension and chronic kidney disease later in life. No recommendations exist for blood pressure (BP) and renal follow up for these patients. Aim: To compare BP and serum and urinary kidney markers between preterm-born adolescents and term-born controls. Methods: BP measurements in 51 preterm-born (≤32 weeks gestational age) and 82 term-born adolescents at the age of 10–15 years were conducted. Stepwise regression analysis explored the association between BP and participant characteristics. Kidney markers measured in the serum and urine were creatinine, neutrophil gelatinase-associated lipocalin (NGAL), and uromodulin. Kidney markers measured in the serum were cystatin C, beta-2 microglobulin, and beta trace protein. Results: Systolic BP was significantly higher in preterm boys compared with term boys, but not in girls, and low birth weight was associated with higher BP in boys. In the preterm group, maternal hypertension/preeclampsia and adolescent height were associated with higher systolic BP. Serum creatinine and NGAL were significantly higher in the preterm group. Conclusions: Our study confirms an inverse sex-dependant relationship between birth weight and BP at adolescent age. The higher serum creatinine and NGAL in the preterm group may indicate that premature birth affects kidney function in the long term.

14 September 2021 in Pediatric Rheumatology
Verified
Journal Article
Open access
PDF file
TWTatjana Welzel
Tatjana Welzel
AWAnna L. Wildermuth
Anna L. Wildermuth
NDNorbert Deschner
Norbert Deschner
SBSusanne M. Benseler
Susanne M. Benseler
JKJasmin B. Kuemmerle-Deschner
Jasmin B. Kuemmerle-Deschner
Background: Autoinflammatory diseases (AID) are rare chronic conditions with high disease burden, affecting children and adults. Clinically and genetically confirmed, AID can be effectively treated with targeted cytokine inhibition. In contrast, for patients with clinical AID symptoms without pathogenic gene variants, no treatment recommendations are available. Colchicine is approved and established as effective, safe and low-cost first-line therapy in Familial Mediterranean Fever. Up to now, efficacy data for colchicine in children with a clinical AID diagnosis without pathogenic gene variants are rare. This pilot study was performed to evaluate the effectiveness of colchicine in children with a clinical diagnosis of AID without pathogenic gene variants. Methods: A pilot cohort study of consecutive children with active clinical AID without pathogenic gene variants treated with colchicine monotherapy was performed between 01/2009 and 12/2018. Demographics, clinical and laboratory characteristics were determined serially. Colchicine dosing and safety were documented. Physician estimate of disease activity was captured on visual analogue scales (VAS). Primary outcome: Complete response (PGA ≤2 plus CRP ≤0.5 mg/dL and/or SAA ≤10 mg/L) at last follow-up. Secondary outcomes: partial/no response, flare characteristics and requirement for rescue therapies. Analysis: Nonparametric comparison of disease activity measures. Results: A total of 33 children were included; 39% were female. Median age at colchicine start was 3.8 years, median follow-up was 14.1 months. Clinical AID diagnoses included CAPS (24%), FMF (27%), PFAPA (43%) and unclassified AID (6%). At baseline, overall disease activity was moderate (PGA 4), inflammatory markers were elevated (CRP 12.1 mg/dL; SAA 289.2 mg/L), and 97% reported febrile flares. Outcome: 55% achieved complete response, 35% showed partial response and 58% had no febrile flares at last follow-up. Inflammatory markers (SAA: p < 0.0001, CRP: p < 0.005) and disease activity (p < 0.0001) decreased significantly. Overall, 93% of children experienced improvement of flare characteristics. Conclusion: Colchicine was found to be effective and safe in children with a clinical AID diagnosis in the absence of pathogenic gene variants. Colchicine is a low-cost treatment option for non-organ threatening AID.